{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-035941","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.739049+00:00","generated_at":"2026-05-23T04:57:20.375398+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relmada reports 90% ORR at any time point in Phase 2 NDV-01 trial for NMIBC","bullets":["90% (18/20) achieved high-grade disease-free status at any time point; 85% ORR at 3 months.","100% complete response in CIS patients (2/2); 88.8% high-grade recurrence-free survival in papillary disease.","NDV-01 well tolerated; no treatment-related AEs >Grade 1, no discontinuations due to AEs.","Study continues enrolling; 26 patients enrolled, 20 reached 3-month assessment, 7 at 6 months.","Administration time <10 minutes; data support potential bladder-sparing outpatient therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-035941","json":"https://secwatch.observer/filing/0001213900-25-035941.json","markdown":"https://secwatch.observer/filing/0001213900-25-035941.md","text":"https://secwatch.observer/filing/0001213900-25-035941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025035941/0001213900-25-035941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025035941/ea0239764-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T04:57:20.375398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}